Taking a 6,000-Compound Cannabis Plant Through the FDA ft. Joel Stanley and Dr. Marcel Bonn-Miller

Joel Stanley co-founded Charlotte's Web and spent a decade building the most standardized botanical cannabis operation in the world. Then he left to start Ajna Biosciences. The FDA quietly opened a botanical drug development pathway in 2016 that most of the cannabis industry, and most investors, have never heard of. Dr. Marcel Bonn-Miller has spent 23 years in cannabinoid research, built the world's largest cannabis research registry alongside Johns Hopkins, and now serves as the scientific backbone behind the most advanced botanical drug program in the space. Their lead drug, AJA-001, is a full-spectrum Charlotte's Web derived formula targeting irritability and aggression in autism spectrum disorder. It contains over 6,000 identified compounds. It is backed by British American Tobacco through a partnership called Defloria. And it is about to enter phase two clinical trials. This is not a supplement story. This is FDA drug development, the same approval groups, the same clinical rigor, the same regulatory pathway as Pfizer or Lilly, applied to a plant that has been used as medicine for centuries. What most investors get wrong is the risk profile. Because these cannabinoid molecules have decades of real world human use data, botanical drugs can advance directly to phase two. New synthetic chemical entities cannot. The front end is harder because you are characterizing thousands of compounds instead of one. The back end is substantially de-risked because the safety data already exists. That is a different equation than conventional pharma, and almost no one in the investment community understands it yet. Inside this episode: ●Why the green rush buried the cannabis medical thesis and what that cost the industry ●How Charlotte's Web standardized a 6,000-compound plant to pharmaceutical specifications ●The FDA botanical drug pathway that has existed since 2016 and why most investors have never heard of it ●AJA-001, the autism pipeline, and the British American Tobacco partnership behind it ●Novel cannabinoid compounds being discovered and categorized that do not exist in any known scientific database ●Why full-spectrum botanical medicine requires lower doses for equivalent efficacy compared to synthetic isolates ●How AI and supercomputing are accelerating compound identification in botanical drug discovery ●Why organic botanical medicine will be a real choice at the pharmacy counter sooner than most people expect 00:00 Why Medical Validation Remains a Challenge for Cannabis 00:12 The FDA Approval Process for Plant-Based Medicines 01:03 Historical Market Dynamics and Their Impact on Cannabis Perception 02:48 Removing the Veil: How Science Can Validate Cannabinoid Therapies 03:15 The Complexity of Plant Molecules and Real-World Evidence 06:20 Focus in Drug Development: The Case of Autism Spectrum Disorder 07:10 The Impact of Charlotte's Web and Media Hype 08:52 Balancing Hype and Reality in Cannabinoid Medicine 10:01 Legitimization of Cannabis Research in Academia 12:10 The Evolution of Cannabis Research and Acceptance 13:54 The Future of Botanical Medicine and Academic Research 16:15 The Long Road of Drug Development for Cannabis-Based Medicines 20:50 Introducing AJA-001: A Botanical Drug for Autism 22:44 Standardization and Characterization of Botanical Drugs 24:01 Partnerships and Funding in Botanical Drug Development 24:40 Challenges of Multi-Compound Botanical Drugs 27:28 Reproducibility and Quality Control in Botanical Manufacturing 29:06 FDA Pathways for Botanical Drugs and New Chemical Entities 34:29 Identifying and Characterizing Thousands of Plant Compounds 39:48 The Role of AI and Supercomputing in Drug Discovery 41:11 Balancing Exploration and Focus in Botanical Research 44:38 What the World Will Understand About Cannabinoids in 10 Years 47:24 The Promise of Botanical Medicine Over Single Molecule Drugs Guest Links: AJNA Biosciences Website https://ajnabiosciences.com/ LinkedIn https://www.linkedin.com/company/ajna-biosciences/posts/?feedView=all Instagram @ajnabiosciences Charlotte’s Web Website https://www.charlottesweb.com/ LinkedIn https://www.linkedin.com/company/charlottesweb/posts/?feedView=all Instagram @charlotteswebcbd Joel Stanley LinkedIn https://www.linkedin.com/in/joel-stanley-2885116b/ Joel Stanley Instagram @joel.stanley Dr. Marcel Bonn-Miller LinkedIn https://www.linkedin.com/in/marcel-bonn-miller-897a581/ Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared global podcast The Dime is a top 10 Cannabis Podcast 🎥 YouTube: The Dime 📸 Instagram: The Dime https://www.newton-insights.com/